Ovid Therapeutics, Inc. is hitting the pause button on its program to develop OV101 (gaboxadol) for Angelman syndrome following the failure of the Phase III NEPTUNE trial. The company plans a full analysis of trial data and further discussions with the US Food and Drug Administration.
Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III
Company Pauses OV101 Program Based On NEPTUNE Results
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.
More from Neurological
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The Texas-based firm is giving up on the investigational Alzheimer’s therapy after a second Phase III failure left it with nowhere to go in the disease.
• By
The FOCUS study met its primary and key secondary endpoints, but lack of statistical significance on the higher dose and a crowded market raised questions.
More from Therapy Areas
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.